Biogen is set to pay $877 million (€772 million) to buy Nightstar Therapeutics for its pipeline of gene therapies. The takeover will give Biogen control of clinical-phase ophthalmology assets that could get to market ahead of drugs in development at rival gene therapy shops. Since spinning out of Oxford University in 2013, Nightstar has advanced two gene therapies targeting retinal indications through the clinic using VC and IPO monies. Source: Fierce Biotech 4/3/2019